Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (479)	8/16/1999 9:12:00 AM
From: scaram(o)uche	Read Replies (2) of 717

biz.yahoo.com Monday August 16, 8:02 am Eastern Time Company Press Release SOURCE: QLT Phototherapeutics Inc. QLT and CIBA Vision announce regulatory submission seeking approval of Visudyne therapy for wet AMD in the United States ATLANTA and VANCOUVER, Aug. 16 /CNW-PRN/ - CIBA Vision Corporation, the eye care unit of Novartis AG, and QLT PhotoTherapeutics Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing clearance for Visudyne(TM) therapy for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 50 in the western world. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next